BioXcel Therapeutics, Inc.
BTAIQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.28M
Close$
Share Statistics
| Market cap | $2.28 Million |
|---|---|
| Enterprise Value | $93.89 Million |
| Dividend Yield | $- (NaN%) |
| Earnings per Share | $- |
| Beta | 0.19 |
| Outstanding Shares | - |
Return
| Return on Equity | 61.37% |
|---|---|
| Return on Assets | -246.05% |
| Return on Invested Capital | 52.36% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 126.54 |
| Enterprise Value to EBIT | -1.65 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 1.11 |
| Debt to Equity | -0.9 |
Revenue Sources
No data
Insider Trades
Next Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-1.01
Average shareholder expectationRevenue Estimate
$484,630
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About BioXcel Therapeutics Inc
29 employees
CEO: Vimal Mehta BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in th...